Due to its prevalent mutations in various cancers, the TERT promoter serves as a promising biomarker for cancer diagnosis and prognosis. The detection of TERT promoter mutations can aid in identifying cancer subtypes and evaluating the aggressiveness of tumors. Moreover, these mutations can be detected in circulating tumor DNA (ctDNA), providing a non-invasive method for monitoring disease progression and response to therapy.
